This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
CXCL12 / Stromal cell-derived factor 1 · IHC design guide
Design Immunohistochemistry for CXCL12
Plan chromogenic IHC on paraffin sections for secreted CXCL12 (UniProt). Use the observed cytoplasmic, nuclear and plasma staining to interpret tissue sections, while allowing for staining beyond producing cells (HPA tissue IHC; UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
CXCL12 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | Secreted (UniProt); cytoplasmic, nuclear and plasma staining observed (HPA tissue IHC) | |
| Staining pattern | Most tissues show cytoplasmic and nuclear staining; plasma is positive (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6 HIER, heat-mediated (datasheet A00053-2) | |
| Positive control | Testis | |
| Negative control | Adipose tissue+4 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Keep fixation consistent across sections. (standard IHC practice; not target-specific) | |
| Caveat | Secreted CXCL12 may stain beyond its producing cells (UniProt). | |
| Regulation | Gamma is enriched in heart (UniProt). | |
| Isoform / epitope | Seven isoforms; signal peptide cleaved; epitope coverage unknown (UniProt). |
Section 1
Recommended CXCL12 IHC & IF Protocols
The catalog antibody’s IHC-P protocol (datasheet A00053-2) is followed by published CXCL12 staining protocols for rat periodontal ligament (PMC4012992) and human pleural tissue microarrays (PMC3085597).
| Sample | Paraffin-embedded human endometrial carcinoma tissue; fixative not specified (datasheet A00053-2) |
| Fixation | Image fixative and duration unreported (datasheet A00053-2); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat retrieval: Citrate pH 6, 20 min (datasheet A00053-2) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% goat serum (datasheet A00053-2) |
| Primary antibody | Rabbit anti-CXCL12, 0.5-1μg/ml (datasheet A00053-2) |
| Primary incubation | Overnight at 4 °C (datasheet A00053-2) |
| Detection | Streptavidin-biotin complex (SABC), DAB chromogen (datasheet A00053-2) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | CXCL12-positive staining in leydig cells of testis (HPA tissue IHC: Medium). HPA tissue profile: Cytoplasmic and nuclear expression in most tissues with additional plasma positivity. No signal in the no-primary control. |
💡Decision noteStart with heat-mediated citrate retrieval at pH 6 (datasheet A00053-2); the pleural tissue protocol also uses citrate at pH 6.0 (PMC3085597).
Section 2
What Is the Expected CXCL12 Staining Pattern?
CXCL12 is secreted and has no transmembrane segment (UniProt P48061 topology). HPA reports cytoplasmic and nuclear staining in most tissues, with additional plasma positivity, but cautions that a secreted protein’s RNA and protein locations can differ (HPA tissue IHC: Approved). Leydig cells provide a documented medium-intensity tissue signal (HPA: Testis, Leydig cells, Medium).
| Leydig cells show a discernible cytoplasmic signal, with or without nuclear staining. | This fits the documented medium Leydig-cell result and HPA’s broader compartment profile (HPA: Leydig cells, Medium; HPA: cytoplasmic and nuclear). Assess intensity relative to matched controls; the HPA level is a reference observation, not a required score for every section (HPA tissue IHC). |
| Staining is confined to sharp cell borders, with no cytoplasmic signal. | A membrane-only pattern does not match the reported tissue profile, and CXCL12 has no transmembrane segment (HPA: cytoplasmic and nuclear; UniProt P48061 topology). Review morphology and detection controls before interpreting the border signal as CXCL12. HPA-reported nuclear staining alone is not, by itself, a wrong compartment (HPA tissue IHC). |
| An HPA-listed negative cell population stains as strongly as the positive comparator. | For example, adipocytes and bone-marrow hematopoietic cells were not detected in the supplied HPA observations (HPA: Adipocytes, Not detected; HPA: Hematopoietic cells, Not detected). Unexpected staining raises cross-reactivity or endogenous detection activity; it does not prove either cause (general IHC practice). Compare staining within the same run. |
| Color spreads across tissue spaces and unrelated structures, obscuring cell boundaries. | Diffuse deposition is difficult to score as a cell-specific result (general IHC practice). CXCL12 is secreted, and HPA also reports plasma positivity, so extracellular signal is possible (UniProt P48061: Secreted; HPA: plasma positivity). A uniformly dirty slide still warrants background controls before biological interpretation. |
| Leydig cells show no discernible staining in a technically adequate section. | This conflicts with the supplied medium-level observation (HPA: Testis, Leydig cells, Medium). Check that the relevant cells are present, then review antibody and detection controls (general IHC practice). One negative run does not establish that CXCL12 is absent; HPA’s result is an observed reference, not a guarantee for each specimen. |
💡Expected CXCL12 appearanceA credible positive is discernible, approximately medium staining in Leydig cells, chiefly assessed in the HPA-reported cytoplasmic and nuclear compartments; uniform staining of unrelated cells or crisp membrane-only outlines warrants control review (HPA: Leydig cells, Medium; HPA: cytoplasmic and nuclear; UniProt P48061 topology).
| Secretion and compartment | CXCL12 is secreted and lacks a transmembrane segment (UniProt P48061 topology). HPA nevertheless reports cytoplasmic and nuclear tissue staining plus plasma positivity (HPA tissue IHC). Read those as observed IHC locations; the record does not establish the mechanism of nuclear signal or identify every extracellular deposit. |
| Processing and isoforms | UniProt lists a signal peptide at residues 1–21, mature chains beginning at residues 22 or 24, and seven isoforms (UniProt P48061 processing; isoforms). These facts can matter when checking an antibody’s documented epitope, but no epitope is supplied here. They cannot predict which isoform the catalog antibody detects. |
| Choice of tissue comparator | HPA reports medium staining in Leydig cells and no detection in the listed adipocytes and bone-marrow hematopoietic cells (HPA tissue IHC). Use these as cell-level comparators. UniProt’s high tissue expression in liver, pancreas and spleen does not specify which cells will stain by this IHC assay (UniProt P48061 tissue specificity). |
| Antibody evidence and RNA comparison | The supplied antibody CAB017564 has IHC status Approved; the record does not give Enhanced status (HPA antibodies: CAB017564, IHC Approved). HPA explicitly warns that RNA and protein locations can differ for a secreted protein (HPA tissue IHC). Neither an RNA map nor Approved status settles an ambiguous slide on its own. |
| Retrieval and chromogenic detection | Antigen retrieval, blocking and control of endogenous detection activity are general paraffin-IHC workflow considerations (general IHC practice). No CXCL12-specific retrieval condition, dilution or fixation sensitivity is supplied. Evaluate such settings against the documented positive and negative cell populations without assigning an unsupported target-specific effect. |
| Situation | Likely cause | Next action |
|---|---|---|
| Leydig-cell signal is absent. | The cells may be missing from the section, or staining or detection may have failed; the reference level is Medium (HPA: Testis, Leydig cells). | Confirm Leydig-cell morphology and inspect a run control; review retrieval, antibody dilution and detection steps as general IHC checks. Do not infer a CXCL12-specific fixation effect from this result (general IHC practice). |
| Adipocytes or bone-marrow hematopoietic cells stain strongly. | Those populations were not detected in the supplied HPA tissue observations; cross-reactivity or endogenous detection activity is possible (HPA tissue IHC; general IHC practice). | Compare with Leydig cells in the same run and inspect an appropriate no-primary detection control. Reassess antibody concentration and blocking as general IHC checks before calling the unexpected cells positive (general IHC practice). |
| The whole section has diffuse chromogenic color. | Nonspecific background or endogenous detection activity may obscure cell-specific staining (general IHC practice). Plasma positivity and secretion also make extracellular signal plausible in some locations (HPA tissue IHC; UniProt P48061: Secreted). | Check the no-primary control and whether cell boundaries remain interpretable; review washing and blocking as general IHC checks. Do not equate uniform background with the HPA-reported plasma result (general IHC practice; HPA: plasma positivity). |
| Only cell membranes have crisp outlines. | This differs from HPA’s reported cytoplasmic and nuclear tissue profile; CXCL12 has no transmembrane segment (HPA tissue IHC; UniProt P48061 topology). | Inspect matched controls and cell morphology, then reassess the scoring call. A border pattern alone is insufficient evidence of CXCL12 localisation in this record (general IHC practice; HPA tissue IHC). |
| Protein staining appears inconsistent with tissue RNA or with UniProt’s high-expression tissues. | HPA warns that RNA and protein locations can differ for secreted CXCL12; UniProt’s tissue summary does not provide cell-level IHC scores (HPA tissue IHC; UniProt P48061 tissue specificity). | Score the actual stained cells and compartments, and compare them with HPA’s cell-level observations. Record any mismatch without assigning it to fixation or an unreported antibody epitope (HPA tissue IHC; general IHC practice). |
| Q: Can this tissue-IHC pattern specify the expected IF/ICC result? | A: HPA lists CXCL12 as secreted but provides no main ICC-IF location or cell lines with ICC-IF images (HPA subcellular ICC-IF). | Use the separate IF/ICC guide for that application. Treat the IHC tissue pattern as context, not an IF/ICC localisation claim; this record supplies no IF/ICC protocol (HPA subcellular ICC-IF; HPA tissue IHC). |
Experiment evidence
IHC & IF images showing CXCL12 staining
A00053-2 · IHCIHC analysis of CXCL12 using anti-CXCL12 antibody (A00053-2). CXCL12 was detected in paraffin-embedded section of human endometrial carcinom
A00053-2 · IHCIHC analysis of CXCL12 using anti-CXCL12 antibody (A00053-2). CXCL12 was detected in paraffin-embedded section of rat spleen tissues. Heat m
A00053-2 · IFIF analysis of CXCL12 using anti-CXCL12 antibody (A00053-2). CXCL12 was detected in a paraffin-embedded section of human hepatitis tissue. H
A00053-3 · IFImmunocytochemistry of CXCL12 in HeLa cells with CXCL12 antibody at 5 μg/mL.
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000107562-CXCL12/tissue/cerebral+cortex#imid_4478748
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000107562-CXCL12/tissue/colon#imid_4478690
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000107562-CXCL12/tissue/liver#imid_4478675
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000107562-CXCL12/tissue/kidney#imid_4478676
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for CXCL12 IHC & IF
🧪Run testis first and score Leydig cells for CXCL12 staining (HPA: Medium in Leydig cells). Use adipose tissue adipocytes as the biological negative (HPA: Not detected in adipocytes); on the testis slide, use cells without specific signal to judge background, but do not treat them as validated CXCL12-negative cells (HPA: only Leydig cells listed in the supplied positive row).
Positive control tissue: Testis (Leydig cells, HPA Medium)
Negative control tissue: Adipose tissue (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for CXCL12; derive a cell-line control from the positive tissue's cell type (Leydig cells) and confirm it by RNA or western blot first.
Technical controls: Include a no-primary, secondary-only control and a concentration-matched rabbit IgG isotype control (caption: rabbit primary antibody; standard IHC practice); confirm specificity with CXCL12 knockout tissue or a peptide-block control if the immunizing peptide is available (standard IHC practice). For chromogenic testis sections, block endogenous peroxidase and check endogenous biotin background when using the caption’s biotin-based detection (caption: biotinylated secondary and SABC/DAB; standard IHC practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported in the supplied evidence, and the selected A00053-2 paraffin-section caption does not state a fixative (selected-SKU IHC caption: fixative unreported). The demonstrated IHC workflow uses heat retrieval in citrate buffer at pH 6 for 20 minutes, but the evidence does not establish whether retrieval is essential or whether frozen sections or IF are easier (selected-SKU IHC caption). No testis-specific artefact is documented in the supplied evidence; assess chromogenic background with the detection controls (HPA: Medium in testis Leydig cells; selected-SKU IHC caption: SABC/DAB).
HPA tissue IHC evidence for CXCL12
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Secreted protein, tissue location of RNA and protein is expected to differ.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Testis | Leydig cells | Medium | Protein (IHC) | HPA → |
Undetected expression · recommended negative controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | Adipocytes | Not detected | Protein (IHC) | HPA → |
| Adrenal gland | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Appendix | Glandular cells | Not detected | Protein (IHC) | HPA → |
| Bone marrow | Hematopoietic cells | Not detected | Protein (IHC) | HPA → |
| Breast | Adipocytes | Not detected | Protein (IHC) | HPA → |
Section 3
Advanced CXCL12 IHC Tips
Troubleshooting CXCL12 chromogenic IHC in paraffin sections, with one entry on adapting the staining strategy to IF.
Which retrieval conditions should I try first for weak CXCL12 staining?
Start with heat-mediated retrieval in citrate buffer at pH 6 for 20 minutes (datasheet A00053-2). That condition was used for CXCL12 detection in a paraffin section of human endometrial carcinoma with the catalog antibody (datasheet A00053-2). If staining remains weak, compare a modestly adjusted heating time on adjacent sections while keeping the antibody concentration and detection steps constant (standard IHC practice). Include a section processed with the documented condition in each comparison, and assess signal alongside tissue damage and background (standard IHC practice). The image caption does not state the fixative, so its retrieval result cannot establish performance across fixation conditions (datasheet A00053-2).
Could fixation explain variable CXCL12 staining between paraffin blocks?
Target-specific fixation sensitivity is unknown because the selected paraffin-section caption does not state its fixative (datasheet A00053-2). Record fixative, fixation duration, block age and section handling for each case, then compare sections under the same citrate pH 6 retrieval and detection conditions (standard IHC practice; datasheet A00053-2). Use an internal tissue reference or a concurrently stained reference section to distinguish a block-level problem from a staining-run problem (standard IHC practice). Because CXCL12 is secreted, interpret differences in cellular and extracellular signal cautiously, but do not assign a particular pattern to fixation without a controlled comparison (UniProt P48061 subcellular location; standard IHC practice).
How should I assess cytoplasmic, nuclear and extracellular CXCL12 signal?
CXCL12 is annotated as secreted and has no transmembrane segment, so membrane outlines alone should not define a positive cell (UniProt P48061 subcellular location and topology). Tissue IHC reports cytoplasmic and nuclear expression in most tissues, with additional plasma positivity, while warning that RNA and protein locations may differ for a secreted protein (HPA tissue IHC). Score cellular and extracellular staining separately, documenting the stained cell type and compartment on matched sections (standard IHC practice). Treat unexpectedly strong nuclear staining as a finding to verify with staining controls and morphology, rather than proof of nuclear function (HPA tissue IHC; standard IHC practice).
Can this stain distinguish CXCL12 isoforms or processed forms?
Do not assign a stained cell to a particular isoform without epitope information and isoform-specific validation (standard IHC practice). The record lists 7 isoforms and a 93-amino-acid precursor with a signal peptide at residues 1–21 and annotated processed chains (UniProt P48061 isoforms and processing). It lists no glycosylation sites or modified residues, but those annotations do not identify what this antibody recognizes in paraffin sections (UniProt P48061 PTMs; standard IHC practice). Request the immunogen or mapped epitope, then check its presence in the relevant isoforms and processed chains before making isoform-level claims (standard IHC practice).
How should I adapt CXCL12 localisation checks for multiplex IF?
Treat the paraffin IHC caption as evidence for chromogenic staining only; it does not establish IF performance for the catalog antibody (datasheet A00053-2). For an IF pilot, multiplex CXCL12 with a validated marker of the cell type being assessed and retain single-stain controls to separate overlapping signals (standard IF practice). Choose a fluorophore whose emission is clear of the specimen’s measured autofluorescence, and inspect unstained tissue before assigning dim extracellular signal (standard IF practice). If the antibody epitope is intracellular, test gentle permeabilisation; if it is extracellularly accessible, compare staining without permeabilisation, because the epitope’s membrane side is not supplied here (standard IF practice; UniProt P48061 subcellular location).
What should I change when DAB staining is diffuse or widespread?
First compare the primary-antibody stain with a no-primary control and inspect where DAB accumulates relative to intact tissue structures (standard IHC practice). The documented run used 1 µg/ml primary overnight at 4°C, a 10% goat-serum block, and biotin-based detection with DAB (datasheet A00053-2). Check peroxidase blocking and, for the documented biotin-based workflow, investigate endogenous biotin as possible contributors to background (standard IHC practice; datasheet A00053-2). If controls are clean but the primary stain remains widespread, compare a lower primary concentration and washing conditions on adjacent sections, preserving the documented condition as a reference (standard IHC practice).
How can I quantify CXCL12 while preserving compartment and cell-type information? ⚠ ANSWER MARKED FOR VERIFICATION
Define the regions, eligible cell types and cytoplasmic, nuclear or extracellular compartments before scoring, then keep those definitions across specimens (standard IHC practice; HPA tissue IHC). For cellular staining, report the percentage of positive eligible cells and an intensity-weighted H-score using the same threshold and counterstain assessment throughout (standard IHC practice). For extracellular deposits, report positive area or staining density per mm² of viable tissue instead of forcing a cell-based score (standard IHC practice; UniProt P48061 subcellular location). Normalize cell counts to eligible cells and area measures to analyzed viable area, and document excluded necrosis and section edges (standard IHC practice).
How do I distinguish true CXCL12 staining from artefact?
Evaluate whether signal follows intact cell morphology or plausible extracellular distribution, since CXCL12 is secreted and lacks a transmembrane segment (UniProt P48061 subcellular location and topology; standard IHC practice). Check cell identity rather than calling every stained cell a source of CXCL12; secreted protein can make protein and RNA locations differ (HPA tissue IHC). Be cautious with isolated membrane outlines, sharp section-edge staining, necrotic areas and signal reproduced in a no-primary control (standard IHC practice). Compare reference regions and controls on the same run, and exclude endogenous peroxidase signal before interpreting DAB as CXCL12 (standard IHC practice).
Boster reagents
Best CXCL12 / Stromal cell-derived factor 1 IHC Antibodies
Real CXCL12 images cover paraffin-section IHC in human and rat tissues (A00053-2 IHC captions), paraffin-section IF in human, mouse and rat tissues (A00053-2 IF captions), and HeLa ICC (A00053-3 ICC caption).
Real IHC data
Anti-CXCL12 Antibody
Cat # A00053-2
Real IF data
Anti-Stromal cell-derived factor 1 CXCL12 Antibody
Cat # A00053-3
A00053-2 has IHC images from human endometrial carcinoma, tonsil and liver cancer sections and rat spleen sections, plus IF images from human hepatitis and tonsil sections and mouse and rat spleen sections (A00053-2 image captions). A00053-3 has an ICC image from HeLa cells and no catalog-listed IHC application (A00053-3 ICC caption; catalog applications).
Which to pick: For paraffin-section tissue IHC, choose A00053-2: its own endometrial carcinoma caption documents citrate retrieval at pH 6 and 1 μg/mL primary antibody; the fixative is unreported (A00053-2 IHC caption). For tissue IF, choose A00053-2, which has paraffin-section IF images; for cultured-cell ICC, choose A00053-3, which has a HeLa ICC image at 5 μg/mL (A00053-2 IF captions; A00053-3 ICC caption). For work across species, A00053-2 is polyclonal and lists human, mouse and rat reactivity, while A00053-3 lists human and mouse reactivity and ICC but no IHC application (catalog dilution and applications; catalog reactivity).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry P48061 (SDF1_HUMAN, Stromal cell-derived factor 1).
- Human Protein Atlas. CXCL12 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. CXCL12 subcellular location (ICC-IF): Secreted.
- Human Protein Atlas. CXCL12 antibody validation summary (1 antibodies).
- CXCL12 is expressed by skeletal muscle cells in tongue oral squamous cell carcinoma. Cancer medicine 2023 — PMC10028106.
- Function of chemokine (CXC motif) ligand 12 in periodontal ligament fibroblasts. PloS one 2014 — PMC4012992.
- The expression of autophagy-related gene CXCL12 in endometriosis associated ovarian cancer and pan-cancer analysis. Frontiers in endocrinology 2025 — PMC11955448.
- The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma. The Journal of pathology 2011 — PMC3085597.
- PubMed PMID:7490086 — UniProt-cited evidence.
- PubMed PMID:16626895 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for CXCL12 (Stromal cell-derived factor 1). Expected localisation Secreted (UniProt); cytoplasmic, nuclear and plasma staining observed (HPA tissue IHC). Antigen retrieval: Citrate pH 6 HIER, heat-mediated (datasheet A00053-2). Validated IHC antibody: A00053-2 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Testis (Leydig cells); negative Adipose tissue. IHC-P workflow on paraffin sections; fixative unspecified. Protocol steps: 1. Sample: Paraffin-embedded human endometrial carcinoma tissue; fixative not specified (datasheet A00053-2); 2. Fixation: Image fixative and duration unreported (datasheet A00053-2); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat retrieval: Citrate pH 6 , 20 min (datasheet A00053-2); 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% goat serum (datasheet A00053-2); 8. Primary antibody: Rabbit anti-CXCL12, 0.5-1μg/ml (datasheet A00053-2); 9. Primary incubation: Overnight at 4 °C (datasheet A00053-2). Watch for: Fixation: Keep fixation consistent across sections. (standard IHC practice; not target-specific); Caveat: Secreted CXCL12 may stain beyond its producing cells (UniProt).; Isoform / epitope: Seven isoforms; signal peptide cleaved; epitope coverage unknown (UniProt).; Regulation: Gamma is enriched in heart (UniProt).. Evidence: UniProt P48061, HPA tissue IHC · Approved, HPA ICC-IF · Secreted, Datasheet A00053-2, PMC4012992, PMC3085597. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/CXCL12/immunohistochemistry-ihc-guide.